drugset
drugset / Trial / NCT05358756

A Study of Bioavailability and Food Effect of SACT-1 and Edurant® Tablets in Healthy Adult Volunteers

NCT05358756 ↗

Phase 1 Completed 16 enrolled Aptorum International Limited
RandomizedCrossoverOpen-labelTreatment

Summary

This was a Phase 1, open-label, randomized, single center, 3-period, 3-sequence, single-dose crossover bioavailability and food effect study between SACT-1 and Edurant® tablet.

Timeline

Start
2021-10-09
Primary completion
2021-11-20
Completion
2021-12-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Rilpivirine Small molecule 150 mg Oral

Indications

No indication recorded.